Research Article

Predicting Overall Survival in Patients with Nonmetastatic Gastric Signet Ring Cell Carcinoma: A Machine Learning Approach

Xiaomei Li,1,2,3 Zhiwei Chen,4 Jing Lin,4 Shouan Wang,2 and Conghua Song1

1Endoscopy Center, The Affiliated Hospital (Group) of Putian University, Putian, 351100 Fujian, China
2School of Basic Medicine, Medical College of Putian University, Putian, 351100 Fujian, China
3Key Laboratory of Translational Tumor Medicine in Fujian Province, Putian University, Putian, 351100 Fujian, China
4Department of Pathology, The Affiliated Hospital (Group) of Putian University, Putian, 351100 Fujian, China

Correspondence should be addressed to Conghua Song; kesongs@email.ncu.edu.cn

Received 20 May 2022; Revised 16 August 2022; Accepted 24 August 2022; Published 13 September 2022

Academic Editor: Laith Abualigah

Copyright © 2022 Xiaomei Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aims. Accurate prediction is essential for the survival of patients with nonmetastatic gastric signet ring cell carcinoma (GSRC) and medical decision-making. Current models rely on prespecified variables, limiting their performance and not being suitable for individual patients. Our study is aimed at developing a more precise model for predicting 1-, 3-, and 5-year overall survival (OS) in patients with nonmetastatic GSRC based on a machine learning approach.

Methods. We selected 2127 GSRC patients diagnosed from 2004 to 2014 from the Surveillance, Epidemiology, and End Results (SEER) database and then randomly partitioned them into a training and validation cohort. We compared the performance of several machine learning-based models and finally chose the eXtreme gradient boosting (XGBoost) model as the optimal method to predict the OS in patients with nonmetastatic GSRC. The model was assessed using the receiver operating characteristic curve (ROC). Results. In the training cohort, for predicting OS rates at 1-, 3-, and 5-year, the AUCs of the XGBoost model were 0.842, 0.831, and 0.838, respectively, while in the testing cohort, the AUCs of 1-, 3-, and 5-year OS rates were 0.749, 0.823, and 0.829, respectively. Besides, the XGBoost model also performed better when compared with the American Joint Committee on Cancer (AJCC) stage. The performance for this model was stably maintained when stratified by age and ethnicity.

Conclusion. The XGBoost-based model accurately predicts the 1-, 3-, and 5-year OS in patients with nonmetastatic GSRC. Machine learning is a promising way to predict the survival outcomes of tumor patients.

1. Introduction

Gastric cancer (GC) is the fifth most frequently diagnosed cancer worldwide and the third leading cause of cancer-related death, which has had a severe influence on global health [1, 2]. In 2020, GC caused more than 1 million new cases and approximately 770,000 deaths, with China alone accounting for approximately half (478,000) of the number of global new cases [3]. According to the WHO classification, GC can be divided into papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, and signet ring cell carcinoma [4]. Among them, gastric signet ring cell carcinoma (GSRC), which is named because a large amount of mucus in cancer cells pushes the nucleus to one side like a ring, is one of the most malignant tumors, accounting for about 3.4%-39% of GC [5, 6]. Though the incidence of GC has declined in the world since the active treatment of Helicobacter pylori, the incidence of GSRC is still increased significantly [7, 8].

GSRC is one of the types of GC with poor tissue differentiation, which has the characteristics of low differentiation, high invasiveness, and poor prognosis. Therefore, patients with GSRC often have a poorer prognosis than other types of GC [9]. According to the previous studies, GSRC is an independent factor for survival prediction, and the 5-year survival rate was 30%-46.1% [10–12]. Besides, medical
decision-making in GSRC is particularly complex and requires weighing treatment benefit against tumor progression. Therefore, the development of accurate models to predict outcomes and make medical decisions is essential to improve the prognosis of patients with GSRC.

Accurate prediction is essential for the survival of patients with nonmetastatic GSRC and medical decision-making. Previous regression analysis-based models have been developed to predict the survival of patients with nonmetastatic GSRC [13–15]. Nonetheless, these models are commonly based on the assumption that each parameter, and the survival outcomes of GSRC were linear dependent (regression model). Hence, one possibility is that these models may weaken the complex relationships, which may include nonlinear associations, nonlinear interactions, or effect modification. In addition, the subjects in these studies were not followed up for more than 5 years. The model constructed based on this may have some bias in survival

| Model           | Training cohort AUC with 95% CI | Testing cohort AUC with 95% CI |
|-----------------|---------------------------------|-------------------------------|
| 1-year survival |                                 |                               |
| KNN             | 0.773 (0.747-0.799)             | 0.715 (0.669-0.760)           |
| Support vector machines | 0.784 (0.757-0.810)         | 0.738 (0.695-0.782)           |
| Random forest   | 0.998 (0.997-0.999)            | 0.725 (0.681-0.770)           |
| XGBoost         | 0.842 (0.819-0.863)            | 0.749 (0.708-0.791)           |
| Neural network  | 0.789 (0.764-0.815)            | 0.706 (0.662-0.751)           |
| 3-year survival |                                 |                               |
| KNN             | 0.801 (0.779-0.823)            | 0.800 (0.766-0.835)           |
| Support vector machines | 0.795 (0.773-0.818)         | 0.812 (0.779-0.846)           |
| Random forest   | 0.997 (0.995-0.998)            | 0.807 (0.773-0.841)           |
| XGBoost         | 0.831 (0.811-0.852)            | 0.823 (0.790-0.854)           |
| Neural network  | 0.814 (0.792-0.836)            | 0.765 (0.729-0.802)           |
| 5-year survival |                                 |                               |
| KNN             | 0.813 (0.791-0.836)            | 0.765 (0.725-0.806)           |
| Support vector machines | 0.813 (0.789-0.836)         | 0.774 (0.733-0.815)           |
| Random forest   | 0.996 (0.994-0.998)            | 0.774 (0.734-0.814)           |
| XGBoost         | 0.838 (0.816-0.858)            | 0.829 (0.793-0.863)           |
| Neural network  | 0.811 (0.787-0.836)            | 0.776 (0.737-0.815)           |
Table 2: Demographic and clinicopathological characteristics of patients.

| Variables                  | All patients ($n = 2127$) | Training cohort ($n = 1488$) | Validation cohort ($n = 639$) |
|----------------------------|----------------------------|-----------------------------|-------------------------------|
| Age (year, mean ± SD)      | 61.6 ± 0.31                | 61.37 ± 0.37                | 62.15 ± 0.55                  |
| Sex (no. (%))              |                            |                             |                               |
| Female                     | 1027 (48.3)                | 701 (47.1)                  | 326 (51)                      |
| Male                       | 1100 (51.7)                | 787 (52.9)                  | 313 (49)                      |
| Race (no. (%))             |                            |                             |                               |
| White                      | 1393 (65.5)                | 975 (65.5)                  | 418 (65.4)                    |
| Black                      | 318 (15)                   | 215 (14.4)                  | 103 (16.1)                    |
| Other                      | 416 (19.5)                 | 298 (20)                    | 118 (18.5)                    |
| Marital status (no. (%))   |                            |                             |                               |
| Married                    | 1284 (60.4)                | 909 (61.1)                  | 375 (58.7)                    |
| Unmarried                  | 843 (39.6)                 | 579 (38.9)                  | 264 (41.3)                    |
| Grade (no. (%))            |                            |                             |                               |
| I                          | 3 (0.1)                    | 1 (0.1)                     | 2 (0.3)                       |
| II                         | 63 (3)                     | 46 (3.1)                    | 17 (2.7)                      |
| III                        | 1992 (93.7)                | 1392 (93.5)                 | 600 (93.9)                    |
| IV                         | 69 (3.2)                   | 49 (3.3)                    | 20 (3.1)                      |
| Size (no. (%))             |                            |                             |                               |
| ≤1 cm                      | 128 (6)                    | 90 (6)                      | 38 (5.9)                      |
| 1-2 cm                     | 278 (13.1)                 | 187 (12.6)                  | 91 (14.2)                     |
| 2-3 cm                     | 315 (14.8)                 | 220 (14.8)                  | 95 (14.9)                     |
| 3-4 cm                     | 258 (12.1)                 | 191 (12.8)                  | 67 (10.5)                     |
| 4-5 cm                     | 218 (10.2)                 | 149 (10)                    | 69 (10.8)                     |
| >5 cm                      | 930 (43.7)                 | 651 (43.8)                  | 279 (43.7)                    |
| Stage A (no. (%))          |                            |                             |                               |
| Localized                  | 652 (30.7)                 | 460 (30.9)                  | 192 (30)                      |
| Regional                   | 1343 (63.1)                | 935 (62.8)                  | 408 (63.8)                    |
| Distant                    | 132 (6.2)                  | 93 (6.3)                    | 39 (6.1)                      |
| T stage (no. (%))          |                            |                             |                               |
| T1                         | 428 (20.1)                 | 296 (19.9)                  | 132 (20.7)                    |
| T2                         | 892 (41.9)                 | 637 (42.8)                  | 255 (39.9)                    |
| T3                         | 609 (28.6)                 | 417 (28)                    | 192 (30)                      |
| T4                         | 198 (9.3)                  | 138 (9.3)                   | 60 (9.4)                      |
| N stage (no. (%))          |                            |                             |                               |
| N0                         | 754 (35.4)                 | 530 (35.6)                  | 224 (35.1)                    |
| N1                         | 739 (34.7)                 | 504 (33.9)                  | 235 (36.8)                    |
| N2                         | 424 (19.9)                 | 299 (20.1)                  | 125 (19.6)                    |
| N3                         | 210 (9.9)                  | 155 (10.4)                  | 55 (8.6)                      |
| Site (no. (%))             |                            |                             |                               |
| Cardia                     | 351 (16.5)                 | 259 (17.4)                  | 92 (14.4)                     |
| Fundus of stomach          | 67 (3.1)                   | 44 (3)                      | 23 (3.6)                      |
| Body of stomach            | 220 (10.3)                 | 162 (10.9)                  | 58 (9.1)                      |
| Gastric antrum             | 543 (25.5)                 | 375 (25.2)                  | 168 (26.3)                    |
| Pylorus                    | 185 (8.7)                  | 131 (8.8)                   | 54 (8.5)                      |
| Lesser curvature of stomach| 111 (5.2)                  | 82 (5.5)                    | 29 (4.5)                      |
| Greater curvature of stomach| 271 (12.7)                | 189 (12.7)                  | 82 (12.8)                     |
| Overlapping/NOS            | 379 (17.8)                 | 246 (16.5)                  | 133 (20.8)                    |
prediction. Therefore, there is no satisfactory survival prediction model for patients with GSRC in real-world practice [16].

To overcome this dilemma, the emerging machine learning has provided an alternative to survival prediction models. Machine learning is a data-driven application of artificial intelligence in which systems learn and improve automatically without explicit programming. It is remarkable that machine learning does not emphasize a certain assumption for data relationships but rather takes into account all possible effects between variables. Thus, machine learning is able to autonomously use datasets to identify new variables and more complex relationships between them. Its applications are rapidly growing in health care and are increasingly being used to develop novel prognostic models for several diseases [17].

Our study is aimed at developing a more precise model for predicting 1-, 3-, and 5-year overall survival (OS) in patients with nonmetastatic GSRC based on machine learning approaches. Instead of single information derived from image segmentation or image recognition based on artificial intelligence, the parameters used in machine learning for modeling here were the more dimensional data derived from clinical practice. The significance of this study not only lies in the development of prediction model for GSRC survival but also includes a call for action to reduce the bias of survival prediction studies in the field of gastrointestinal tumors.

2. Methods

2.1. Data Source and Study Population. The data was collected from the Surveillance, Epidemiology, and End Results (SEER) program with the National Cancer Institute’s SEER∗ Stat software (version 8.3.9, http://seer.cancer.gov/seerstat/). SEER collects cancer diagnoses and survival data for approximately 30% of the US population and benefits from extensive quality review model development. GSRC patients were preliminarily screened according to the International Classification of Diseases in Oncology (ICD-O-3) and histology code (8490/3).

Patients were further screened according to the following criteria: the inclusion criteria were (1) patients diagnosed in 2004–2014, (2) ICD-O-3 identified the primary site as the stomach, (3) patients with only one primary tumor, and (4) patients with complete survival information. The exclusion criteria were (1) patients with distant metastasis of tumor, (2) tumor grade or race or tumor size unknown, (3) TNM or the American Joint Committee on Cancer (AJCC) stage unknown, (4) surgical information unknown, and (5) age less than 15 or more than 90 years old.

We collected the following variables from the SEER database: age, sex, race, marital status, tumor location, tumor size, histologic grade, T stage, N stage, number of regional lymph nodes (LN) examined, AJCC stage, and survival month. Finally, a total of 2127 patients were included in our study and then randomly assigned with R 3.6.1 to the training cohort and the validation cohort at a ratio of 7 to 3. Access to the SEER database does not require formal ethical approval, and its open access policy is included. The detailed screening process for GSRC patients is shown in Figure 1.

### Table 2: Continued.

| Variables                                | All patients (n = 2127) | Training cohort (n = 1488) | Validation cohort (n = 639) |
|------------------------------------------|------------------------|----------------------------|-----------------------------|
| Therapy (no. (%))                        |                        |                            |                             |
| None                                     | 61 (2.9)               | 39 (2.6)                   | 22 (3.4)                    |
| Surgery only                             | 728 (34.2)             | 511 (34.4)                 | 217 (34)                    |
| Chemo/radio only                         | 158 (7.4)              | 113 (7.6)                  | 45 (7)                      |
| Surgery plus chemo/radio                 | 1180 (55.5)            | 825 (55.4)                 | 355 (55.6)                  |
| Regional nodes examined (no. (%))        |                        |                            |                             |
| ≤16                                      | 1192 (56)              | 825 (55.4)                 | 367 (57.4)                  |
| >16                                      | 935 (44)               | 663 (44.6)                 | 272 (42.6)                  |
| AJCC (no. (%))                           |                        |                            |                             |
| I                                        | 686 (32.3)             | 476 (32)                   | 210 (32.9)                  |
| II                                       | 473 (22.2)             | 325 (21.8)                 | 148 (23.2)                  |
| III                                      | 637 (29.9)             | 450 (30.2)                 | 187 (29.3)                  |
| IV                                       | 331 (15.6)             | 237 (15.9)                 | 94 (14.7)                   |
| Overall survival (no. (%))               |                        |                            |                             |
| 1 years                                  | 1540 (72.4)            | 1080 (72.6)                | 460 (72)                    |
| 3 years                                  | 895 (42.1)             | 623 (41.9)                 | 272 (42.6)                  |
| 5 years                                  | 625 (29.4)             | 440 (29.7)                 | 185 (29)                    |

2.2. Study Design. Race was classified into three types: White, Black, and other. Marital status was recorded as married and unmarried. The grade was classified into four types: well-differentiated (grade I), moderately differentiated (grade II), poorly differentiated (grade III), and undifferentiated/anaplastic (grade IV). Historic stage A was recorded as localized, regional, or distant. T stage was recorded as T1, T2, T3,
Figure 2: Continued.

(a)

(b)
Figure 2: Continued.
Figure 2: A comparison of the area under the receiver operating characteristic curve (AUROC) of different machine learning models in predicting (a) 1-, (b) 3-, and (c) 5-year overall survival (OS) in patients with nonmetastatic GSRC in the training cohort and (d) 1-, (e) 3-, and (f) 5-year OS in the validation cohort. KNN: k-nearest neighbor; SVM: support vector machines; RF: random forest; NT: neural networks; XGB: an eXtreme gradient boosting.
Figure 3: Continued.
Figure 3: Continued.
Figure 3: A comparison of the area under the receiver operating characteristic curve (AUROC) of eXtreme gradient boosting (XGB) and the American Joint Committee on Cancer (AJCC) stage in predicting (a) 1-, (b) 3-, and (c) 5-year overall survival (OS) in the training cohort and (d) 1-, (e) 3-, and (f) 5-year OS in the validation cohort.
Table 3: Performance of XGBoost models in OS stratified by age.

|               | Age < 65 years* | Age ≥ 65 years* |
|---------------|-----------------|-----------------|
| 1-year survival | 0.710 (0.677-0.744) | 0.749 (0.718-0.781) |
| 3-year survival | 0.796 (0.771-0.822) | 0.832 (0.804-0.859) |
| 5-year survival | 0.805 (0.779-0.832) | 0.849 (0.820-0.878) |

*AUC with 95% CI.

Table 2. The mean age was 61.6 ± 0.31 years old. 1100 (51.7%) were male. Most patients were White (65.5%), and 15% were Black. 60.4% of patients were married. The primary stage was grade III (93.7%), the central stage A was regional (63.1%), and the main AJCC stage was I (32.3%). Meanwhile, 930 patients (43.7%) had tumor size >5 cm. T1 (41.9%), N0 (35.4%), and regional nodes examined ≤16 (56%) accounted for predominance. The gastric antrum was the most common site for GSRC (25.5%). Among all included patients, the OS rates at 1, 3, and 5 years were 72.4%, 42.1%, and 29.4%, respectively.

2.3. Model Development. To improve the accuracy of our model, the following variables were included: age, sex, race, marital status, tumor location, tumor size, histologic grade, T stage, N stage, and the number of regional LNs examined. The training cohort was used to train an eXtreme gradient boosting model (with the XGBoost package in R), and the validation cohort was used to verify the model’s accuracy.

Before choosing and optimizing the XGBoost model, we performed rigorous exploratory analyses of k-nearest neighbor (KNN), support vector machines (SVM), random forest (RF), and neural networks (NT). Separate models were generated with hyperparameter tuning to optimize their performance for each outcome, and all models underwent validation using the validation cohort. The receiver operating characteristic curve (ROC), the area under ROC (AUC), and the accuracy were used to assess the precision and specificity of models. The AUC ranges from 0 to 1, with 1 indicating perfect concordance, 0.5 indicating no better concordance than chance.

The preliminary findings suggested that RF and XGBoost appeared to perform better than other models in the training cohort (Table 1). However, in the validation group, the performance of the RF algorithm is poor, meaning that the RF algorithm may have an overfitting phenomenon. Hence, we chose the XGBoost algorithm as our final model. XGBoost is a regression tree algorithm based on machine learning, which combines the outputs of other decision trees to improve the classification. XGBoost is a recently developed gradient tree boosting algorithm, which is scalable and allows faster calculations [21].

2.4. Statistical Analysis. All analyses were performed using R statistical software 3.6.1 (http://www.r-project.org). For normally distributed data, continuous variables were expressed as mean ± standard deviation (SD). Categorical variables were presented as proportions. Variables with P < 0.05 were taken into consideration as significant.

3. Results

3.1. Baseline Characteristics of Patients. Figure 1 shows our data assembly process. Between 2004 and 2014, a total of 7124 patients from the SEER database with histologically confirmed GSRC were enrolled in our study. Of these, 3562 patients who presented with evidence of distant metastases were excluded. 1198 patients had missing data for tumor grade or race or tumor size, 215 patients did not have TNM or AJCC stage information, 3 patients did not have surgical information, and 19 people outside of the study age range (15–90 years) were also excluded.

The final study population included 2127 patients. Baseline characteristics of the study cohort were shown in Table 2. The mean age was 61.6 ± 0.31 years old. 1100 patients were male. Most patients were White (65.5%), and 15% were Black. 60.4% of patients were married. The primary stage was grade III (93.7%), the central stage A was regional (63.1%), and the main AJCC stage was I (32.3%). Meanwhile, 930 patients (43.7%) had tumor size >5 cm. T1 (41.9%), N0 (35.4%), and regional nodes examined ≤16 (56%) accounted for predominance. The gastric antrum was the most common site for GSRC (25.5%). Among all included patients, the OS rates at 1, 3, and 5 years were 72.4%, 42.1%, and 29.4%, respectively.

Next, we established the ROC curve and calculated the corresponding AUC to compare the XGBoost model and AJCC staging accuracy in predicting patients’ OS. As shown in Figure 3, the 1-, 3-, and 5-year AUCs of the XGBoost model were 0.842, 0.831, and 0.838, respectively, while in the testing cohort, the AUCs of 1-, 3- and 5-year OS rates were 0.749, 0.823, and 0.829, respectively.

In our study, model performance was marginally better in men aged 65 years or older than in men younger than 65 (Table 3 and Figure 4). And the model was the best in predicting the 5-year OS rate of people aged 65 years or older (AUC: 0.849, 95% CI: 0.820-0.878). Then, we tested performance in different ethnic groups. The XGBoost model also performed well (Table 4 and Figure 5). The significance of the predictors in the XGBoost model is presented in Figure 6. The most important predictor was the T stage, followed by age, therapy, primary site, and tumor size.
Figure 4: Continued.
Figure 4: Continued.
4. Discussion

GSRC is a highly malignant type of GC, accounting for 8-30% of GC cases [22, 23]. Although the incidence rates of GSRC are low, its reported 5-year survival rate was only 15.9% [24]. Besides, the prognosis of GSRC remains controversial. Previous studies demonstrated that the survival of GSRC patients was relatively better than other histological types in the early stage. Probably because the tumor of GSRC is more frequently found in early-stage GC, the early-stage GSRC has a lower risk of lymph node metastasis [12, 25–27]. However, study about the accurate prognosis of early GSRC is rare. Hence, it is imperative to establish a predictive model to guide the clinical work better.

In this study, we used a large and public dataset to construct and validate a machine learning-trained prognostic model for predicting 1-, 3-, and 5-year overall survival (OS) in patients with nonmetastatic GSRC. To our best knowledge, our study is the first to use the SEER cohort to establish a machine learning model for predicting OS rate in patients with nonmetastatic GSRC.

AJCC staging system currently used prognostic GC patients. However, the current GC monitoring prediction model is not suitable for the tracking of GSRC. Notably, the AJCC staging system does not account for some significant clinicopathological characteristics, such as age, gender, and treatment method, which were all related to patients’ survival. In the present study, our model incorporated the above characteristics into machine learning, and the results showed our model’s performance was better than the AJCC staging system.

Prior research has been carried out to develop simple multivariable regression predictive models for GSRC. Xu et al. developed a prognostic nomogram based on log odds of positive lymph nodes to predict the OS and CSS rate of GSRC [12]. However, the model was not good at predicting the 1-year OS rate (AUC: 0.768), and its 5-year OS rate prediction ability showed only a slight preponderance over AJCC. Besides, this study selected patients diagnosed from 2010 to 2015 from the SEER database, and the database only has follow-up data up to 2018. Hence, there may be a certain deviation for this study in predicting the 5-year OS rate.

The studies carried out by Wang et al., Zhang et al., and Guo et al. also had similar problems [13, 14, 28]. Wei et al.

Table 4: Performance of XGBoost models in OS stratified by race.

|                | White* | Black* | Other* |
|----------------|--------|--------|--------|
| 1-year survival| 0.744 (0.716-0.771) | 0.729 (0.666-0.792) | 0.755 (0.699-0.810) |
| 3-year survival| 0.816 (0.794-0.839) | 0.788 (0.737-0.838) | 0.849 (0.812-0.885) |
| 5-year survival| 0.817 (0.793-0.842) | 0.848 (0.800-0.896) | 0.840 (0.801-0.878) |

*AUC with 95% CI.
Figure 5: Continued.
Figure 5: Continued.
collected 1,030 patients from the SEER database and constructed CSS prognostic model. They found that patients who received postoperative radiotherapy had a better prognosis than patients who underwent surgery alone [29]. Guo et al. constructed a nomogram predicting lymph node metastasis [30]. However, these studies have limited population selection, and the predictive ability is not good.

Many consider machine learning as a “black box,” in which a computer generates predictions. Unfortunately, most clinicians have a limited understanding of the machinations involved to generate these predictions. While medicine remains behind other disciplines in utilizing machine learning, its predictive power has been demonstrated with increasing frequency [16, 17, 31, 32]. Compared with the
traditional parametric model, machine learning has more flexible, accurate, and robust predictive capabilities [17]. Besides, machine learning methods based on specific samples with explicit characteristic attributes are more suitable for identifying individual patients [33].

In recent years, the research on medical image diagnosis based on artificial intelligence has increased significantly. Different image vision classification and image segmentation tools can be used to identify abnormalities caused by diseases. Compared with manpower, the main advantages of image information capture technology based on artificial intelligence are fast detection speed, high accuracy, and stable results. However, instead of single information derived from image segmentation or image recognition based on artificial intelligence, the parameters used in machine learning for modeling here were more dimensional data from clinical practice. XGBoost is a regression tree algorithm based on machine learning, which combines the outputs of other decision trees to improve the classification and allows faster calculations.

XGBoost, a regression tree algorithm for faster calculations, is recently developed as an open source project. The whole execution process of XGBoost is easy and can run as packages in a freely available language R 3.6.1. In our study, by comparing several other algorithms, we chose the XGBoost algorithm for modeling. XGBoost algorithm has the advantages of regularization and parallel processing, which made the model perform well in our research [34].

Although our model has a satisfactory accuracy, several limitations also deserve to be mentioned. First, though SEER is a huge population-based database, some critical information was not explained, potentially making the models even more accurate. Second, the model was constructed using a retrospective nationwide database. Therefore, the current analysis of the patient population could not exclude the possibility of selection bias. Finally, external validation is lacking in this study. Further study is needed to validate the advantages of the model in survival prediction.

In conclusion, this study is the first to explore the performance of machine learning in predicting OS in patients with nonmetastatic GSRC. XGBoost is a regression tree algorithm based on machine learning, which combines the outputs of other decision trees to improve the classification and allows faster calculations. The XGBoost-based model accurately predicts the 1-, 3-, and 5-year OS in patients with nonmetastatic GSRC. Machine learning is a promising way to predict the survival outcomes of tumor patients.

### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| GSRC | Gastric signet ring cell carcinoma |
| OS | Overall survival |
| SEER | Surveillance, Epidemiology, and End Results |
| ROC | Receiver operating characteristic curve |
| XGBoost | eXtreme gradient boosting |
| AJCC | American Joint Committee on Cancer |
| GC | Gastric cancer |
| ICD | International Classification of Diseases |
| LN | Lymph node |
| KNN | K-nearest neighbor |
| SVM | Support vector machines |
| RF | Random forest |
| NT | Neural networks |

### Data Availability

Available datasets were analyzed in this study. This data can be found in https://seer.cancer.gov/data/. Further enquiries can be directed to the corresponding author.

### Conflicts of Interest

The authors declare no conflict of interest.

### Authors’ Contributions

C. Song was responsible for the study concept and design. X. Li was responsible for the acquisition of data. C. Song and X. Li were responsible for the analysis and interpretation of data. X. Li drafted of the manuscript. C. Song, Z. Chen, J. Lin, and S. Wang critically revised the manuscript. C. Song was responsible for the statistical analysis. C. Song and X. Li obtained funding. The authors had full access to the data and take full responsibility for the results. All authors contributed to the article and approved the submitted version.

### Acknowledgments

The authors acknowledge the efforts of the SEER program in the creation of the SEER database (authorized username: 17015-Nov2018). Funding was provided by the Natural Science Foundation of Fujian Province of China (grant nos. 2017J01347, 2022J011441, and 2022J05258) and High-Level Introduction of Talent Research Start-Up Fund, Putian University (grant no. 2021070).

### References

[1] E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken, and F. Lordick, “Gastric cancer,” The Lancet, vol. 396, no. 10251, pp. 635–648, 2020.
[2] J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, and R. Sitarz, “Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies,” International Journal of Molecular Sciences, vol. 21, no. 11, p. 4012, 2020.
[3] Z. Luo, Z. Rong, and C. Huang, “Surgery strategies for gastric cancer with liver metastasis,” Frontiers in Oncology, vol. 9, p. 1353, 2019.
[4] N. Assarzadegan and E. Montgomery, “What is new in the 2019 World Health Organization (WHO) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing,” Archives of Pathology & Laboratory Medicine, vol. 145, no. 6, pp. 664–677, 2021.
[5] Y. Li, Z. Zhu, F. Ma, L. Xue, and Y. Tian, “Gastric signet ring cell carcinoma: current management and future challenges,” Cancer Management and Research, vol. Volume 12, pp. 7973–7981, 2020.
[6] T. Tsukamoto, M. Nakagawa, Y. Kiriyama, T. Toyoda, and X. Cao, “Prevention of gastric cancer: eradication of
helicobacter pylori and beyond,” *International Journal of Molecular Sciences*, vol. 18, no. 8, p. 1699, 2017.

[7] T. Taboure, M. Dhooge, A. Rouquette et al., “Gastric signet ring cell adenocarcinoma: a distinct entity,” *Presse Medica (Paris, France: 1983)*, vol. 43, no. 4, pp. 353–357, 2014.

[8] S. Zhao, L. Lv, K. Zheng, Y. Tian, J. C. Zheng, and C. G. Jiang, “Prognosis and biological behavior of gastric signet-ring cell carcinoma better or worse: a meta-analysis,” *Frontiers in oncology*, vol. 11, article 603070, 2021.

[9] Y. C. Kao, W. L. Fang, R. F. Wang et al., “Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer,” *Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*, vol. 22, no. 2, pp. 255–263, 2019.

[10] X. Kong, X. Zhang, Y. Huang, L. Tang, Q. Peng, and J. Li, “Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells,” *Cancer management and research*, vol. 9, pp. 573–580, 2017.

[11] C. H. Tseng, W. L. Fang, K. H. Huang et al., “The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach,” *Journal of the Chinese Medical Association: JCMA*, vol. 83, no. 2, pp. 141–147, 2020.

[12] Z. Xu, J. Jing, and G. Ma, “Development and validation of prognostic nomogram based on log odds of positive lymph nodes for patients with gastric signet ring cell carcinoma,” *Chinese Journal of Cancer Research = Chung-kuo yen cheng yen chiu*, vol. 32, no. 6, pp. 778–793, 2020.

[13] H. Wang, Y. Peng, Q. Huang, J. Wu, and M. Zhang, “Prognostic nomograms for nonelderly adults with gastric signet ring cell carcinoma,” *BioMed Research International*, vol. 2021, Article ID 1274527, 15 pages, 2021.

[14] S. Zhang, Y. Liu, Z. Jiao et al., “Early signet ring cell carcinoma of the stomach is related to favorable prognosis and low incidence of lymph node metastasis,” *Journal of Surgical Oncology*, vol. 114, no. 5, pp. 607–612, 2016.

[15] Z. Wang, X. Zhang, J. Hu, W. Zeng, and Z. Zhou, “Clinicopathological features and outcomes in patients undergoing radical resection for early gastric cancer with signet ring cell histology,” *Journal of Visceral Surgery*, vol. 152, no. 6, pp. 357–361, 2015.

[16] C. T. Tang, Y. Chen, and C. Zeng, “Prognostic analysis of gastric signet ring cell carcinoma and mucinous carcinoma: a propensity score-matched study and competing risk analysis,” *Aging*, vol. 12, no. 21, pp. 22059–22077, 2020.

[17] Q. Guo, Y. Wang, J. An, S. Wang, X. Dong, and H. Zhao, “A prognostic model for patients with gastric signet ring cell carcinoma,” *Technology in Cancer Research & Treatment*, vol. 20, p. 15303382110279, 2021.

[18] F. Wei, H. Lyu, S. Wang, Y. Chu, and F. Chen, “Postoperative radiotherapy improves survival in gastric signet-ring cell carcinoma: a SEER database analysis,” *Journal of Gastric Cancer*, vol. 19, no. 4, pp. 393–407, 2019.

[19] C. G. Guo, Y. J. Chen, H. Ren et al., “A nomogram for predicting the likelihood of lymph node metastasis in early gastric signet ring cell carcinoma: a single center retrospective analysis with external validation,” *Medicine*, vol. 95, no. 46, article e5393, 2016.

[20] H. In, I. Solsky, B. Palis, M. Langdon-Embry, J. Ajani, and T. Sano, “Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the National Cancer Data-base,” *Annals of Surgical Oncology*, vol. 24, no. 12, pp. 3683–3691, 2017.

[21] Y. Dabiri, A. Van der Velden, K. L. Sack, J. S. Choy, G. S. Kasab, and J. M. Guccione, “Prediction of left ventricular mechanics using machine learning,” *Frontiers in Physics*, vol. 7, p. 117, 2019.

[22] K. J. Kwon, K. N. Shim, E. M. Song et al., “Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach,” *Gastric Cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*, vol. 17, no. 1, pp. 43–53, 2014.

[23] S. Pernot, T. Voron, G. Perkins, C. Lagorce-Pages, A. Berger, and J. Taieb, “Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge,” *World Journal of Gastroenterology*, vol. 21, no. 40, pp. 11428–11438, 2015.

[24] X. F. Yang, L. Yang, X. Y. Mao, D. Y. Wu, S. M. Zhang, and Y. Xin, “Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: a comparative study,” *World Journal of Gastroenterology*, vol. 10, no. 5, pp. 750–754, 2004.

[25] T. Imamura, S. Komatsu, D. Ichikawa et al., “Early signet ring cell carcinoma of the stomach is related to favorable prognosis and low incidence of lymph node metastasis,” *Nature Reviews Gastroenterology & Hepatology*, vol. 16, no. 5, pp. 612, 2016.

[26] Z. Wang, X. Zhang, J. Hu, W. Zeng, and Z. Zhou, “Clinicopathological features and outcomes in patients undergoing radical resection for early gastric cancer with signet ring cell histology,” *Journal of Visceral Surgery*, vol. 152, no. 6, pp. 357–361, 2015.

[27] C. T. Tang, Y. Chen, and C. Zeng, “Prognostic analysis of gastric signet ring cell carcinoma and mucinous carcinoma: a propensity score-matched study and competing risk analysis,” *Aging*, vol. 12, no. 21, pp. 22059–22077, 2020.

[28] Q. Guo, Y. Wang, J. An, S. Wang, X. Dong, and H. Zhao, “A prognostic model for patients with gastric signet ring cell carcinoma,” *Technology in Cancer Research & Treatment*, vol. 20, p. 15303382110279, 2021.